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Nuclear factor kappa BThe pathophysiology of chronic inﬂammatory pain remains poorly understood. In this context, we developed an
experimental model inwhich successive daily injection of prostaglandin E2 (PGE2) for 14 days into rat hind paws
produces a persistent state of hypernociception (i.e. decrease in mechanical nociceptive threshold). This state
persists for more than 30 days after discontinuing PGE2 injection. In the present study, we investigated the
participation of nuclear factor kappa B (NF-κB), in themaintenance of this process. Mechanical hypernociception
was evaluated using the electronic von Frey test. Activation of NF-κB signaling was measured through the
determination of NF-κB p65 subunit translocation to the nucleus of dorsal root ganglion neurons (DRG) by
immunoﬂuorescence and western blotting. Herein, we detected an increase in NF-κB p65 subunit translocation
to the nucleus of DRG neurons along with persistent inﬂammatory hypernociception compared with controls.
Intrathecal treatment with either dexamethasone or PDTC (NF-κB activation inhibitor) after ending of the
induction phase of the persistent inﬂammatory hypernociception, curtailed the hypernociception period
as well as reducing NF-κB p65 subunit translocation. Treatment with antisense oligonucleotides against the
NF-κB p65 subunit for 5 consecutive days also reduced persistent inﬂammatory hypernociception. Inhibition
of PKA and PKCε reduced persistent inﬂammatory hypernociception, which was associated with inhibition of
NF-κB p65 subunit translocation. Together these results suggest that peripheral activation of NF-κB by PKA and
PKC in primary sensory neurons plays an important role in maintaining persistent inﬂammatory pain.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Chronic pain is frequently associatedwith functional alterations in the
central and peripheral nervous systems, including an increase in primary
sensitive ﬁbers excitability and drastic changes in cellular phenotype
with expression of additional neurotransmitters, receptors and enzymesX, cyclooxygenase; DRG, dorsal
lucocorticoid receptor; IL-1β,
actor kappa B; PIH, persistent
carbamate; PGE2, prostaglandin
ology, Ribeirao Preto Medical
Ribeirao Preto — USP, Avenida
zil. Tel.: +55 16 3602 3222;
, shferrei@fmrp.usp.br(Liu andWood, 2011). Concerning chronic pain due to inﬂammation, its
underlying pathophysiology remains poorly understood, especially
because its genesis involves mechanisms that are different from those
that trigger acute inﬂammatory pain. One impediment is that there are
few experimental models that mimic chronic inﬂammatory pain states
in humans. Although some models, such as Complete Freund's Adjuvant
(CFA)-induced inﬂammation, could be maintained for long periods, they
mimic unresolved acute inﬂammation. The clinically important chronic
pain cases are those in which the inﬂammatory process has been already
resolved, but the pain persists. Therefore, a suitable model is essential to
study the mechanisms underlying chronic inﬂammatory pain, which is a
requisite for evaluating potentially effective novel therapies.
In an attempt to elucidate the mechanisms of chronic inﬂammatory
pain,we developed an experimentalmodel. This state is achieved in rats
or mice by successive daily injection of prostaglandin E2 (PGE2) for
14 days, which produced a persistent inﬂammatory hypernociception
(i.e. decrease in mechanical nociceptive threshold) lasting more than
30 days after discontinuing PGE2 injections (Ferreira et al., 1990). Our
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generated by frequent periods of sensitization of the primary nocicep-
tive ﬁbers and has duration of several weeks. It is important to note
that the persistent inﬂammatory hypernociception state is blocked
by analgesics of peripheral action, such as dipyrone and N-methyl
morphine, but it is easily restored by small doses of PGE2 or dopamine,
indicating the contribution by peripheral mechanisms to this phenom-
enon (Ferreira et al., 1990).
The molecular events associated with themaintenance of persistent
inﬂammatory hypernociception are not completely understood. A
critical step in the development andmaintenance of chronic pain states
is the phenotypic change in primary nociceptive neurons probably
occurring through gene modulation. In this context, it is possible
that transcription factors, such as nuclear transcription factor kappa B
(NF-κB) might play a role in rendering neuronal phenotypic changes.
The NF-κB/Rel family has ﬁve members: p50, p52, p65/RelA, RelB, and
c-Rel. NF-κB is mainly composed of p65/p50 heterodimers and
homodimers of p50 or p65. In its normal state, NF-κB exists as a
cytoplasmic complex with its inhibitory protein IκBα. During its
activation, IκBα is phosphorylated and subsequently degraded,
allowing NF-κB translocation into the nucleus, where it modulates the
transcription of target genes (Li and Verma, 2002). The increasing inter-
est in characterizing NF-κB involvement in mediating inﬂammatory
pain stems from the large number of genes and cellular processes that
it regulates. This transcription factor contributes to controlling develop-
mental processes, neuronal plasticity, synaptic transmission, death and
cellular defense. Some of the genes whose expression NF-κBmodulates
are nitric oxide synthase, cyclooxygenase (COX), cytokines, adhesion
molecules, acute-phase proteins and dinorphine (Barnes and Adcock,
1997; O'Neill and Kaltschmidt, 1997). Regarding inﬂammatory pain, it
was shown that intrathecal treatment with NF-κB inhibitors reduces
thermal and mechanical hyperalgesia after peripheral inﬂammation
induced by CFA in rats (Lee et al., 2004). Moreover, mice lacking the
NF-κB p50 subunit present with reduced nociception in both phases
of the formalin test, and reduced thermal hypernociception accompa-
nied by reduced COX-2 expression in the spinal cord (Niederberger
et al., 2007).
Taking into account these evidences, in the present study, we inves-
tigated whether activation of NF-κB is involved in the maintenance
of persistent inﬂammatory hypernociception. As maintenance of
persistent inﬂammatory hypernociception depends on a continuous
activation of PKA and PKCε, we determined here if inhibition of these
kinases has corresponding inhibitory effects on both NF-κB activation
and this process (Villarreal et al., 2009b).
2. Material and methods
2.1. Animals
Male Wistar rats (180–220 g) were housed in temperature-
controlled rooms (22–25 °C), with access to water and food ad libitum.
All experiments were conducted in accordance with the International
Association for the Study of Pain guidelines (Zimmermann, 1983) and
with the approval of the Ethics Committee of the Faculty of Medicine
of Ribeirao Preto (University of Sao Paulo). The animals were used
only in a single experimental group.
2.2. Drugs
The agents used in this study were PGE2, dexamethasone, H89 and
PDTC (Sigma; St Louis, MO, USA). PKCεV1–2 peptide (a selective PKCε
inhibitor) was obtained from SynPep Corp (Dublin, CA, USA). Stock
PGE2 solutions were prepared by dissolving the drug in ethanol
(Merck) followed by dilution with 0.9% saline to decrease the ethanol
concentration to 1%. Dexamethasone and PDTC were dissolved in 0.9%
saline. PGE2 was administered in a volume of 100 μL with a 27-gaugehypodermic needle, which was subcutaneously introduced near the
third digit, with the needle tip reaching the middle of the plantar area.2.3. Evaluation of mechanical nociceptive threshold
The mechanical nociceptive threshold was measured with an
electronic pressure-meter. The rats were placed in acrylic cages
(12 × 20× 17 cm in height) on a wire grid ﬂoor, 15 to 20min before be-
ginning tests. After this adaptation period, the paws were poked 2 to 3
times. Before paw stimulation, the animals were docile quiet, without
any exploratory or toilet movements and not resting over their paws.
In these experiments, a pressure-meter, which consisted of a hand-
held force transducer adapted with a 0.7-mm2 polypropylene tip (elec-
tronic von Frey anesthesiometer; IITC Inc. Life Science Instruments,
Woodland Hills, CA) was used. The investigator was trained to apply
the polypropylene tip perpendicularly in between the ﬁve distal foot-
pads with a gradual increase in pressure. A tilted mirror below the
grid provided a clear view of the animal hindpaw. The test consisted
of poking the hindpaw to provoke a ﬂexion reﬂex followed by a clear
ﬂinch response after the paw withdrawal. The electronic pressure-
meter automatically recorded the stimulus intensity when the paw
was withdrawn. The maximal value of calibration range in which the
pressure was linearly detectable by the equipment was 80 g. The ani-
mals were tested before and after treatments, and the results are
expressed as the delta reaction force (grams) that was calculated by
subtracting the value of the measurements of the right paw (treated
paw) from that of the left paw (control naïve paw). Before starting the
experiments, it was conﬁrmed that there were no differences in the
basal responses of the right and left paws (Vivancos et al., 2004).2.4. Induction of persistent inﬂammatory hypernociception
Before starting the experiments, the basal responses of rats were
recorded in the left and right hind paws. There are two phases of
persistent inﬂammatory hypernociception. In the ﬁrst phase, rats
received daily intraplantar (i.pl.) injections of PGE2 (100 ng/100 μL)
for 14 consecutive days (i.e. induction period). This dose of PGE2 was
selected in previous studies in our laboratory (Ferreira et al., 1990;
Sachs et al., 2002). The control group received vehicle (saline 100 μL)
during the same period. Mechanical inﬂammatory hypernociception
was evaluated daily before (0 h) and after (3 h) a PGE2 injection
with the electronic pressure meter test as described above. After the
end of the induction period, the maintenance phase starts in which
it is not necessary to administer additional inﬂammatory agents such
as PGE2 to maintain persistent inﬂammatory hypernociception for
30 days. Mechanical hypernociception was also evaluated during
themaintenance phase at indicated time points depending on the treat-
ment protocol.2.5. Oligodeoxynucleotide p65 NF-κB subunit targeting
Antisense oligonucleotides (ODNs) were used to induce p65 NF-κB
subunit knock-down in rat DRG neurons. The ODN sequence design
wasbased on a previous study (Kitaoka et al., 2004): antisense sequence
(5′-AAA CAG ATC GTA CAT GGC-3′); mismatch sequence (5′-GCC ATG
GAC GAT CTG TTT-3′) were derived from the respective antisense
sequences by scrambling eight bases. Rats received an intrathecal
injection of either antisense, once a day (20 μg/day/10 μL saline) or
mismatch (20 μg/day/10 μL saline) for 5 days. The treatment started at
day 1 after the induction of persistent inﬂammatory hypernociception.
Five days after ODN treatments, the L4–L6 DRGs on the ipsilateral
side where PGE2 was injected was removed to assess antisense ODN
treatment efﬁcacy.
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p65 NF-κB subunit mRNA expression levels were evaluated in rat
DRG receiving antisense and mismatch treatments using real-time
PCR. Brieﬂy, rats were euthanized by decapitation under anesthesia
and the DRGs (3 from each rat; L4, L5 and L6) were harvested, homog-
enized in and left in contact with 1 mL of TRIzol reagent (for 10 min)
and total RNA was extracted. The purity of total RNA was measured
with a spectrophotometer and the wavelength absorption ratio
(260/280 nm) was between 1.8 and 2.0 for all preparations. Reverse
transcription of total RNA to cDNA was carried out with reverse tran-
scription reaction (Superscript II, Gibco Life Technologies, Grand Island,
NY, USA). Real-time PCR quantitative mRNA analysis was performed in
an ABI Prism 7500 Sequence Detection System using the SYBR-green
ﬂuorescence system (Applied Biosystems,Warrington, UK) for quantiﬁ-
cation of amplicons. RT-PCR was performed in a 20 μL reaction volume
and carried out with heating at 95 °C (10 min), and then 40 cycles of
94 °C (1 min), 56 °C (1 min) and 72 °C (2 min). Melting curve analysis
was performed (65–95 °C) in order to verify that only one product
was ampliﬁed. Samples with more than one peak were excluded. The
data were analyzed with the comparative cycle threshold (CT)method.
The expression of β-actin mRNA was used as an internal control in all
samples. The primers used were as follows: p65 NF-κB subunit (sense,
5′-CGCTTTATCAAGGTCCTTACTC-3′; antisense, 5′-GCGTTTTGAGATAT
TTGAAGGT-3′) and GAPDH (sense, 5′CTGAGTATGTCGTGGAGTCTA-3′;
antisense, 5′CTGCTTCACCACCTTCTTGAT-3′).
2.7. Intrathecal injections
Intrathecal (i.t.) ODN injections were performed under isoﬂurane
anesthesia (2%) (Ferreira and Lorenzetti, 1996). The dorsal fur of each
rat was shaved, the spinal column was arched, and a 26-gauge needle
was directly inserted into the subarachnoid space, between the L4 and
L5 vertebrae. Correct i.t. positioning of the needle tip was conﬁrmed
by manifestation of a characteristic tail ﬂick response. A 10 μL volume
containing the test agent was slowly injected with a 100 μL Hamilton
microsyringe. The animals regained consciousness approximately
1 min after discontinuing the anesthetic.
2.8. DRG immunoﬂuorescence
An immunoﬂuorescence assay was used to identify a semi-
quantitative translocation of p65 NF-κB subunit to the nucleus of rat
DRG neurons during the maintenance of persistent inﬂammatory
hypernociception. All groups of rats were deeply anesthetizedwith ure-
thane and perfused through the ascending aorta with saline, followed
by 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (4 °C).
After the perfusion, L5 DRG was dissected out, post ﬁxed in the same
ﬁxative for 2 h, which was then, replaced overnight with 30% sucrose.
All of the DRGs were embedded in OCT, and DRG sections (14 μm)
were cut in a cryostat and processed for immunoﬂuorescence. All of
the sections were blocked with 2% BSA in 0.3% Triton X-100 for 1 h at
room temperature and then incubated for 2 h at 4 °C with a polyclonal
rabbit p65 NF-κB subunit (1:400, Santa Cruz, CA, USA). After washing
with PBS, sections were incubated with AlexaFluo-594 conjugated
secondary antibodies (Molecular Probes, Carlsbad, CA, USA) for 1 h at
room temperature. Subsequently, sections were washed with PBS, and
incubated with DAPI (1:3000) for nuclear staining. Finally, they were
coverslipped with ﬂuoromount and sealed with enamel. The absence
of cross-reactivity of the secondary antibodies was veriﬁed by omitting
primary antibody during incubation. Double-labeled sections were
analyzed by confocal laser microscope (TCS SP5, Leica Leisertechnik,
Heidelberg, Germany). Color images from double-labeling experiments
were adjusted for contrast and brightness using Adobe Photoshop 9.0
software (Adobe, San Jose, CA).2.9. Western blotting analysis
After ODN p65 NF-κB treatment, rats were decapitated and the
dorsal root ganglia (DRG L4-6) were removed surgically. DRGs were
homogenized in a lysis buffer containing protease inhibitors (Sigma;
St Louis, MO, USA). The protein concentrations of the lysate were deter-
mined using the Bradford method. The protein samples were separated
on an SDS/PAGE gel and transferred to nitrocellulose membranes
(AmershamPharmacia Biotech) followed by the incubationwith prima-
ry antibody against rabbit anti-p65 NF-κB antibody (sc-372, Santa Cruz
Biotechnology) in ﬁltered TBS-T buffer containing 5% milk powder
overnight at 2–8 °C. Membranes were then incubated for 1 h at room
temperature with an HRP-conjugated secondary antibody (1:5000;
Jackson ImmunoResearch). The blots were visualized in an ECL solution
(Amersham Pharmacia Biotech, Little Chalfont, UK) and exposed in a
ChemiDoc MP Imaging System (Bio-Rad Laboratories, Hercules CA,
USA).
2.10. Nuclear extract obtainment and western blotting
After induction of persistent inﬂammatory hypernociception, rats
were treated with PDTC (30 ng/day once a day for 4 days), H-89 (H89,
27 μg/50 μL/paw unique injection) PKCε inhibitor (3 μg/50 μL/paw
unique injection) or vehicle. Twenty-four hours after the treatments,
rats were decapitated and the dorsal root ganglia (DRG L4–6) were re-
moved surgically. DRGswere initially homogenized in a tube containing
180 μL of a buffer containing Tris 10mM, NaCl 10mM,MgCl2 3mM, DTT
500 μM, EGTA 100 μM and protease inhibitor cocktail (Sigma, St. Louis,
MO, USA) in ultrapure water, pH adjusted to 7.4. Extracts were brieﬂy
centrifuged at 1000 g, for 30 s and supernatants were collected. To
cytoplasm lyses, 20 μL of triton X-100 5%was added in the supernatants
and vortexed by 30 s. This solution was maintained in ice for 5 min.
Resultant extracts were centrifuged at 6000 g for 6 min. Pellets formed
were washed twice with buffer containing Tris 10 mM, NaCl 10 mM,
MgCl2 3mM, DTT 500 μM, EGTA 100 μMand protease inhibitor cocktail,
and lysedwith 50 μL of Rippa buffer (Sigma, St. Louis, MO, USA) contain-
ing protease inhibitor cocktail. These samples were vortexed for 2 min
and centrifuged at 16000 g for 10 min. The resulting supernatant was
taken as nuclear extract.
Samples of nuclear extracts had their protein content quantiﬁed by
the Bradford method. Proteins were separated using electrophoresis
gel SDS-PAGE (10% of polyacrylamide) followed by transfer to a nitro-
cellulose membrane. Nitrocellulose membrane was incubated with
rabbit anti-p65 NF-κB antibody (sc-372, Santa Cruz Biotechnology)
1:250 in ﬁltered TBS-T buffer containing 5% milk powder overnight at
2–8 °C. Secondary antibody (anti-rabbit, IgG) conjugated with peroxi-
dase (1:5000) diluted in TBS-T buffer containing 5%milk was incubated
with themembrane by 1 h. The characterization of nuclear extracts was
performed usingmouse anti-nucleophosmin antibody (Sigma, St. Louis,
MO,USA) 1:300 inmilk 5%, followed by incubationwith secondary anti-
mouse conjugated with peroxidase 1:10,000. Mouse anti-actin (Sigma,
St. Louis,MO, USA) antibody 1:10,000 inmilk 5%, followed by secondary
anti-mouse conjugated with peroxidase 1:10,000 was used as a
negative control of nuclear protein purity, but no signiﬁcant signal
was observed (data not shown). The blots were visualized in an ECL
solution (ECL western blotting Systems, GE Healthcare, Little Chalfont,
BKM, UK) and exposed in a ChemiDoc XRS+System(Bio-Rad Laborato-
ries, Hercules CA, USA).
2.11. Data analyses and statistics
All resultswere analyzed using Prisma 4.0 software and are presented
as the means ± S.E.M. The experiments were repeated at least twice.
The number of rats indicated in the legends is relative to one single ex-
periment and it was used for statistical analyses. Rats were used once.
Differences between groups were evaluated by analysis of variance
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were considered to be signiﬁcant at P b 0.05.
3. Results
3.1. Induction of persistent inﬂammatory hypernociception
Fig. 1 diagrammatizes the induction (panel A) and maintenance
(panel B) phases of the persistent inﬂammatory hypernociception
induced by PGE2. The nociceptive threshold was evaluated by testing
on each of 14 consecutive days the effect of applying increasingpressure
(electronic von Frey test) on hind paw withdrawal on rats repeatedly
injected during time with either PGE2 or vehicle. Mechanical
hypernociception was evaluated before and 3 h after PGE2 injection of
during the induction phase of persistent inﬂammatory hypernociception.
After this induction phase, the nociceptive threshold was evaluated once
a day for up to 30 days, which is the maintenance phase. During the ﬁrst
4 days of PGE2 administration, hypernociception peaked at 3 h after in-
jection, followed by restoration to the control level after 24 h (i.e. vehicle
injected). From the sixth to the tenth days (induction phase), the
hypernociception intensity evaluated before the PGE2 injection
was similar to that seen in the third hour after administration of
PGE2 (Fig. 1A). Even though after 10 days, persistent inﬂammatory
hypernociception seems to be established, it was previously veriﬁed
that 14 consecutive days of PGE2 administration are required for inﬂam-
matory hypernociception to persist for up to 30 days (Ferreira et al.,
1990). In fact, therewas already signiﬁcantmechanical hypernociception
on the 15th day (ﬁrst day of themaintenance phase; Fig. 1B) before PGE2
injection compared with the saline injected group. It is noteworthy that
the persistent inﬂammatory hypernociception was not attributable to
possible traumatic inﬂammatory lesions by the repetitive injections,
because the saline treated control animals did not develop mechanical
hypernociception during this period (Fig. 1A and B).
3.2. Inhibition of NF-κB activation reduces the maintenance phase of
persistent inﬂammatory hypernociception
In order to evaluate the participation of NF-κB in themaintenance of
the persistent inﬂammatory hypernociception, rats were treated intra-
thecally with vehicle (saline), dexamethasone or PDTC starting one
day after the end of the induction phase of persistent inﬂammatory
hypernociception. All treatments were performed once a day for 4
consecutive days. These two different NF-κB inhibitors signiﬁcantlyFig. 1. Daily injection of PGE2 induces persistent inﬂammatory hypernociception (PIH).
Panel A shows the induction phase inwhichPGE2 or saline is injected every day. The inten-
sity of mechanical hypersensitivity was assessed twice each day before (0 h) and 3 h
after intraplantar (i.pl.) injection of PGE2 (100 ng/paw) or saline (100 μL/paw) treatments
(indicated arrows). Panel B shows thepersistent phase of hypernociception inwhich there
is no injection of PGE2. Themechanical hypernociceptionwas evaluatedwith an electronic
pressure meter test for rats. Data are expressed as the mean ± SEM of 5 rats per group.
*P b 0.05 compared to saline control group.reduced persistent inﬂammatory hypernociception compared with
their control (Fig. 2A–B).
In an attempt to further explore NF-κB involvement in the mainte-
nance of persistent inﬂammatory hypernociception, ODN antisense
was used to knockdown p65 NF-κB subunit expression, an ODN anti-
sense directed against the p65 NF-κB subunit or an irrelevant mismatch
were injected intrathecally once a day for 5 consecutive days starting
one day after the end of induction of persistent inﬂammatory
hypernociception. Corroborating with pharmacological treatments,
ODN antisense also reduced persistent inﬂammatory hypernociception
(Fig. 3A). Interestingly, persistent inﬂammatory hyperalgesia recovered
after the interruption of ODN treatment (Fig. 3A). The effectiveness of
ODN antisense treatment was conﬁrmed by evaluating p65 subunit of
NFκB mRNA and protein expression in the DRG (L4–6) (Fig. 3B and C).
After the evaluation of persistent inﬂammatory hypernociception,
the group treated with vehicle or PDTC were used to evaluate NF-κB
p65 subunit translocation to DRG neuron nuclei. In agreement
with NF-κB involvement in themaintenance phase of persistent inﬂam-
matory hypernociception, p65 translocation from the cytoplasm to the
nucleus increased as shown in representative western blotting and
immunoﬂuorescence images of rats that received 14 daily injections of
PGE2 compared to saline injected animals (Fig. 4A and B). Moreover,
in agreementwith the behavioral data shown in Fig. 2B, the PDTC treat-
ment diminishedNF-κB p65 subunit translocation toDRGneuronnuclei
(Fig. 4A and B).
3.3. PKA and PKCε inhibition reduces persistent inﬂammatory
hypernociception maintenance and NF-κB translocation
Our laboratory demonstrated that PKA and PKCε are activated during
the maintenance phase of persistent inﬂammatory hypernociception
(Villarreal et al., 2009b). Thus, we determined whether these kinases
could be involved in NF-κB activation. Rats were locally (paw) treated
with H-89 or PKCε inhibitor in the maintenance phase of persistent
inﬂammatory hypernociception. Mechanical hypernociception was
tested for 20 days using the electronic von Frey measurement. After
the evaluation of hypernociception, DRG neurons (L4–6)were harvested
and NF-κB p65 subunit translocation to the nuclei was determined.
As shown before, a single administration of H-89 (PKA inhibitor;
Fig. 5A) or a PKCε inhibitor (Fig. 5B) reduced persistent inﬂammatory
hypernociception (Villarreal et al., 2009b). Importantly, the inhibition
of PKA or PKCε resulted in a reduction in NF-κB p65 subunit transloca-
tion to the nucleus of primary sensory neurons (Fig. 5C andD). These re-
sults suggest that PKA and PKCε activation during the maintenance
phase results in NF-κB activation, which in turn is closely related to
the maintenance of persistent inﬂammatory hypernociception.
4. Discussion
Chronic pain is a serious and debilitating problem that affects many
people worldwide. In an attempt to investigate the mechanisms
involved in genesis of chronic inﬂammatory pain, we developed in the
90s a model in which 14 daily injections of PGE2 induces a state of
persistent inﬂammatory hypernociception that is independent of
further inﬂammatory stimuli. In the present study, we are showing
that the activation of NF-κB in primary nociceptive neurons is critical
to the maintenance of this type of persistent inﬂammatory
hypernociception. Moreover, it seems that PKA and PKCε activation
are responsible for triggering NF-κB activation.
One important characteristic of chronic pain is the fact that even
after the resolution of the inﬂammatory process pain persists. Our
experimental model used in the present study seems to mimic this
state. In fact, even after stopping the administration of PGE2, the
hypernociceptive state is still observed. Besides PGE2, other mediators
such as dopamine, cytokines (e.g. TNF-α and IL-1β) and chemokines
(e.g. IL-8) induce persistent inﬂammatory hypernociception (Sachs
Fig. 2.NF-κBmediates themaintenance phase of persistent inﬂammatory hypernociception (PIH). Persistent inﬂammatory hypernociception was induced by daily injections of PGE2 into
rat paws for 14 days. After the induction phase, rats were treated for 4 days with dexamethasone (50 μg/10 μL/i.t. Panel A) or PDTC (30 ng/10 μL/i.t. Panel B). The mechanical
hypernociception was evaluated daily 3 h after drugs treatment (indicated arrows) with an electronic pressure meter test for rats. Data are expressed as the mean ± SEM of 5 rats per
group. *P b 0.05 compared to PIH group.
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repetitive inﬂammation for a period could be one of the underlying
mechanisms for chronic pain and neuronal plasticity.
The main hypothesis raised to explain persistent inﬂammatory
hypernociception is that phenotypic changes in the primary nociceptive
neurons are responsible for the development of this process. These
phenotypic alterations seem to be dependent on the synthesis of new
proteins, since protein synthesis inhibition reduced persistent inﬂam-
matory hypernociception (Ferreira et al., 1990). Therefore, it is likely
that transcriptional factors might play a role.
Among transcriptional factors, NF-κB is one of the most important
and frequently involved in the production of local proinﬂammatory
cytokines and chemoattractants by resident and migrating cells. This
transcription factor also controls a large number of pro-inﬂammatory
genes, including cytokines, cyclooxygenase-2, inducible nitric oxide
synthase and others (Lee et al., 2009; Ndengele et al., 2008; O'Rielly
and Loomis, 2008). In addition, several studies have shown that NF-κB
is implicated in the pathogenesis of acute and chronic pain either
inﬂammatory or neuropathic.Moreover, it has been shown that a block-
ade of NF-κB alters synaptic plasticity (Mattson and Camandola, 2001).
Herein, we evaluated whether NF-κB participates in the maintenance
of persistent inﬂammatory hypernociception. Firstly, we detected
that pharmacologic inhibition of NF-κB with glucocorticoid or
PDTC reduced the maintenance phase of persistent inﬂammatory
hypernociception.Fig. 3. The p65 NF-κB knockdown reduced persistent inﬂammatory hypernociception (PIH). P
phase, rats were treated with ODN antisense or mismatch anti-NF-κB (20 μg/10 μL/i.t. Panel A
NF-κB p65 subunit mRNA and protein expression in DRG was determined using qPCR and we
and C). Data are expressed as the mean ± SEM of 5 rats per group *P b 0.05 compared to PIH gSupporting these behavioral and pharmacological data, the results
also demonstrate that PDTC treatment reduced NF-κB activation in
DRG neurons of rats during persistent inﬂammatory hypernociception.
Considering that these drugs may have off target effects unrelated to
NF-κB inhibition, we employed a genetic approach using ODN antisense
to knockdown NF-κB p65 subunit expression. As intrathecal ODN
antisense injection inhibited protein expression in peripheral sensory
neurons, this approach is appropriate to selectively investigate the
role of proteins expressed by primary nociceptive neurons (Khasar
et al., 1996). Our results that persistent inﬂammatory hypernociception
was reduced by ODN against p65 subunit, further support that NF-κB is
an important transcription factor in the maintenance phase of persis-
tent inﬂammatory hypernociception.
In accordance with our results, other investigators have shown that
during inﬂammation and injury, respectively, the percentages of acti-
vated NF-κB immunoreactive neurons were signiﬁcantly increased in
dorsal root ganglia and the spinal cord of the rats (Bethea et al., 1998;
Ma and Bisby, 1998). Corroborating these results, NF-κB p50 knockout
mice have a reduced nociceptive response to acute and inﬂammatory
noxious stimulation (Niederberger et al., 2007).
Nevertheless, most of these studies used models of ongoing inﬂam-
mation, such as CFA-induced chronic inﬂammatory pain. In fact, our
model of persistent inﬂammatory hyperalgesia, as far we identify, is
the unique model in which pain hypersensitivity still present, at least,
30 days after discontinuing inﬂammatory stimulus injection. It isIH was induced by daily injections of PGE2 into rat paws for 14 days. After the induction
). Mechanical hypernociception was evaluated before and 3 h after ODNs treatment. The
stern blotting after treatment with ODN antisense anti-p65 NF-κB or mismatch (Panel B
roup.
Fig. 4. Persistent inﬂammatory hypernociception (PIH) induces NF-κB activation. Nuclear p65 NF-κB expression in the DRG neurons of rats submitted to PIH was determined by western
blotting (Panel A) and immunoﬂuorescence (Panel B). One group of rats was treated with PDTC (30 ng/10 μL/i.t.) or vehicle treatment. DAPI staining was used as a nuclear marker
(Panel B). Scale bars 20 μm.
54 G.R. Souza et al. / Pharmacology, Biochemistry and Behavior 134 (2015) 49–56noteworthy that persistent inﬂammatory hyperalgesia recovered after
the interruption of treatment with ODN against p65 NF-κB. Although
the exact explanation for this result is not clear, we could suggest that
after the interruption of ODN treatment there is a turnover of p65 sub-
unit which could be activated again by intracellular signaling pathways
(eg. PKA and PKCε). Therefore, these delightful results indicate that
even after peripheral (local of inﬂammation) stimulation has been
ceased, NF-κB signaling in the dorsal root ganglions still activated and
participate in the maintenance of persistent hyperalgesia.
The maintenance phase of persistent inﬂammatory hypernociception
is dependent on PKA and PKCε, which result in increased expression of
Nav1.8 channels (Villarreal et al., 2009b). Herein, we also veriﬁed that in-
hibition of PKA and PKCε activation reduces the maintenance phase of
persistent inﬂammatory hypernociception, conﬁrming previous a study
withmice and rats (Sachs et al., 2009; Villarreal et al., 2009a). Important-
ly, PKA and PKCε inhibition also diminished the activation/translocation
of NF-κB to the nucleus of DRG neurons. Therefore, it is likely that
the 14 daily injections of PGE2 induce a persistent inﬂammatory
hypernociception that is maintained by PKA- and PKCε activation of
NF-κB in DRG neurons. Since, PKA and PKCε activation is involved in
the up-regulation of Nav1.8 expression during persistent inﬂammatory
hypernociception (Villarreal et al., 2009a), we might speculate that
this event is NF-κB signaling-dependent. It is important to mention
that these results did not prove a direct action of PKA and PKCε
on NF-κB. Nevertheless, there is evidence in the literature indicating
that PKA and/or PKC can induce NF-κB-mediated effects. For instance,
N-nitroso-N-methylurea and N-nitroso-N-ethylurea induce NF-κB acti-
vation via PKC in human keratinocytes (Moon, 2010), TNFα activates
NF-κB in a PKA- and PKCδ-dependent manner (Takahashi et al., 2002),and PKA induces NF-κB-mediated Schwann cell differentiation into a
myelinating phenotype (Yoon et al., 2008). Together these results
can support our hypothesis that during persistent inﬂammatory
hypernociception NF-κB activation is probablymediated by PKA and PKC.
One remarkable point warranting consideration is the locale in
which NF-κB inhibitors are acting after intrathecal injection. We and
others showed that besides acting in the spinal cord cells, substances,
injected intrathecally, can also act in the DRGs (Ferrari et al., 2007;
Gendron et al., 2006; Lorenzetti and Ferreira, 1996). Thus, in the present
study, our hypothesis is that NF-κB inhibitors block translation of
NF-κB-dependent genes by acting at the cell body level in the primary
nociceptive neurons. Although, we evaluated the NF-κB p65 subunit
translocation to the nucleus of primary sensory neurons in the DRGs,
it is still necessary to consider the possibility of a NF-κB inhibitor spinal
effect after intrathecal treatment. Indeed, such an agent could target
glial cells in the spinal cord such as astrocytes and microglia cells,
which are involved in chronic pain maintenance (Pan et al., 2010;
Zhang et al., 2011). For instance, the NF-κB pathway in spinal glial
cells has been implicated in neuropathic pain (Ledeboer et al., 2005;
Meunier et al., 2007). Moreover, chronic constriction of the sciatic
nerve induces microglia activation in the spinal cord (Colburn et al.,
1999) which is dependent in part on NF-κB activation (Wilms et al.,
2003) and probably is involved in nociceptive responses (Watkins
et al., 1997). Even in the DRGs, NF-κB inhibitors could target satellite
glial cells that seem to be participating in the genesis of chronic pain
by producing proinﬂammatory mediators (Souza et al., 2013; Wang
et al., 2011). Therefore, we cannot discard that NF-κB signaling
activation in glial cells can account for the maintenance of persistent
inﬂammatory hypernociception.
Fig. 5. PKA and PKCεmediate NF-κB activation during persistent inﬂammatory hypernociception (PIH). PIH was induced by daily injections of PGE2 for 14 days in the rat paws. After
the induction phase, rats were treatedwith a single dose of PKA inhibitor (H89, 27 μg/50 μL/paw) or PKCε inhibitor (3 μg/50 μL/paw). Mechanical hypernociception was evaluated before
and 3 h after the treatments and once daily for 25 days (Panels A–B). Nuclear p65 NF-κB expression was determined in the DRGs by western blotting (Panel C) and immunoﬂuorescence
(Panel D). Data are expressed as the mean ± SEM of 5 rats per group. *P b 0.05 compared to PIH group. Scale bars: 20 μm.
55G.R. Souza et al. / Pharmacology, Biochemistry and Behavior 134 (2015) 49–56In conclusion, the present study indicates that the activation of NF-κB
signaling in primary sensory neurons is an important event involved in
the maintenance of persistent inﬂammatory hypernociception induced
by PGE2 in rats. The results also indicate that PKA- and PKCε-dependent
pathways might be triggering this signaling. More generally speaking,
peripheral inhibition of NF-κB pathway signaling might be a suitable
approach to control persistent inﬂammatory pain.
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